TOI Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -16.13% compared to The Oncology Institute's net margin of 8.01%. The Oncology Institute's return on equity of -163.45% beat Encompass Health's return on equity of 17.39%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 795.26%. On the other hand Encompass Health has an analysts' consensus of -- which suggests that it could grow by 23.71%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Encompass Health has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.393%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.66% to investors and pays a quarterly dividend of $0.17 per share. The Oncology Institute pays -- of its earnings as a dividend. Encompass Health pays out 17.16% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute quarterly revenues are $99.9M, which are smaller than Encompass Health quarterly revenues of $1.4B. The Oncology Institute's net income of -$16.1M is lower than Encompass Health's net income of $108.2M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Encompass Health's PE ratio is 22.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.04x versus 1.84x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD has a net margin of -16.13% compared to The Oncology Institute's net margin of -156.54%. The Oncology Institute's return on equity of -163.45% beat Kindly MD's return on equity of -201.03%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 795.26%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that The Oncology Institute has higher upside potential than Kindly MD, analysts believe The Oncology Institute is more attractive than Kindly MD.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute pays -- of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend.

The Oncology Institute quarterly revenues are $99.9M, which are larger than Kindly MD quarterly revenues of $647.9K. The Oncology Institute's net income of -$16.1M is lower than Kindly MD's net income of -$1M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.04x versus 2.10x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of -16.13% compared to The Oncology Institute's net margin of 3.8%. The Oncology Institute's return on equity of -163.45% beat Pediatrix Medical Group's return on equity of -30.86%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 795.26%. On the other hand Pediatrix Medical Group has an analysts' consensus of -- which suggests that it could grow by 18.27%. Given that The Oncology Institute has higher upside potential than Pediatrix Medical Group, analysts believe The Oncology Institute is more attractive than Pediatrix Medical Group.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.570, suggesting its more volatile than the S&P 500 by 56.979%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute pays -- of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

The Oncology Institute quarterly revenues are $99.9M, which are smaller than Pediatrix Medical Group quarterly revenues of $511.2M. The Oncology Institute's net income of -$16.1M is lower than Pediatrix Medical Group's net income of $19.4M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.04x versus 0.57x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of -16.13% compared to The Oncology Institute's net margin of 3.29%. The Oncology Institute's return on equity of -163.45% beat US Physical Therapy's return on equity of 1.67%.

The Oncology Institute has a consensus price target of --, signalling upside risk potential of 795.26%. On the other hand US Physical Therapy has an analysts' consensus of -- which suggests that it could grow by 23.35%. Given that The Oncology Institute has higher upside potential than US Physical Therapy, analysts believe The Oncology Institute is more attractive than US Physical Therapy.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.463, suggesting its more volatile than the S&P 500 by 46.285%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 1.95% to investors and pays a quarterly dividend of $0.44 per share. The Oncology Institute pays -- of its earnings as a dividend. US Physical Therapy pays out 164.43% of its earnings as a dividend.

The Oncology Institute quarterly revenues are $99.9M, which are smaller than US Physical Therapy quarterly revenues of $168M. The Oncology Institute's net income of -$16.1M is lower than US Physical Therapy's net income of $5.5M. Notably, The Oncology Institute's price-to-earnings ratio is -- while US Physical Therapy's PE ratio is 53.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.04x versus 2.10x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.